edoc

Items where Author is "Donath, M. Y."

Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Group by: Date | Item Type | Refereed
Jump to: 2016 | 2015 | 2013 | 2012 | 2011
Number of items: 23.

2016

Cavelti-Weder, C. and Timper, K. and Seelig, E. and Keller, C. and Osranek, M. and Lassing, U. and Spohn, G. and Maurer, P. and Muller, P. and Jennings, G. T. and Willers, J. and Saudan, P. and Donath, M. Y. and Bachmann, M. F.. (2016) Development of an Interleukin-1β Vaccine in Patients with Type 2 Diabetes. Molecular Therapy, 24 (5). pp. 1003-1012.

Timper, K. and Dalmas, E. and Dror, E. and Rutti, S. and Thienel, C. and Sauter, N. S. and Bouzakri, K. and Bedat, B. and Pattou, F. and Kerr-Conte, J. and Boni-Schnetzler, M. and Donath, M. Y.. (2016) Glucose-Dependent Insulinotropic Peptide Stimulates Glucagon-Like Peptide 1 Production by Pancreatic Islets via Interleukin 6, Produced by α Cells. Gastroenterology, 151 (1). pp. 165-179.

2015

Sauter, N. S. and Thienel, C. and Plutino, Y. and Kampe, K. and Dror, E. and Traub, S. and Timper, K. and Bedat, B. and Pattou, F. and Kerr-Conte, J. and Jehle, A. W. and Boni-Schnetzler, M. and Donath, M. Y.. (2015) Angiotensin II Induces Interleukin-1β–Mediated Islet Inflammation and β-Cell Dysfunction Independently of Vasoconstrictive Effects. Diabetes, 64 (4). pp. 1273-1283.

Herder, C. and Donath, M. Y.. (2015) Interleukin-1 receptor antagonist: friend or foe to the heart? The Lancet Diabetes & Endocrinology, 3 (4). pp. 228-229.

Timper, K. and Seelig, E. and Tsakiris, D. A. and Donath, M. Y.. (2015) Safety, pharmacokinetics, and preliminary efficacy of a specific anti-IL-1alpha therapeutic antibody (MABp1) in patients with type 2 diabetes mellitus. Journal of Diabetes and its Complications, 29 (7). pp. 955-960.

Herder, C. and Dalmas, E. and Boni-Schnetzler, M. and Donath, M. Y.. (2015) The IL-1 Pathway in Type 2 Diabetes and Cardiovascular Complications. Trends in Endocrinology and Metabolism, 26 (10). pp. 551-563.

2013

Donath, M. Y. and Burcelin, R.. (2013) GLP-1 effects on islets: hormonal, neuronal, or paracrine? Diabetes care, Vol. 36, suppl. 2 , S145-S148.

Boni-Schnetzler, M. and Donath, M. Y.. (2013) How biologics targeting the IL-1 system are being considered for the treatment of type 2 diabetes. British journal of clinical pharmacology, Vol. 76, H. 2. pp. 263-268.

Biason-Lauber, A. and Boni-Schnetzler, M. and Hubbard, B. P. and Bouzakri, K. and Brunner, A. and Cavelti-Weder, C. and Keller, C. and Meyer-Boni, M. and Meier, D. T. and Brorsson, C. and Timper, K. and Leibowitz, G. and Patrignani, A. and Bruggmann, R. and Boily, G. and Zulewski, H. and Geier, A. and Cermak, J. M. and Elliott, P. and Ellis, J. L. and Westphal, C. and Knobel, U. and Eloranta, J. J. and Kerr-Conte, J. and Pattou, F. and Konrad, D. and Matter, C. M. and Fontana, A. and Rogler, G. and Schlapbach, R. and Regairaz, C. and Carballido, J. M. and Glaser, B. and McBurney, M. W. and Pociot, F. and Sinclair, D. A. and Donath, M. Y.. (2013) Identification of a SIRT1 mutation in a family with type 1 diabetes. Cell metabolism, Vol. 17, H. 3. pp. 448-455.

Donath, M. Y. and Dalmas, E. and Sauter, N. S. and Boni-Schnetzler, M.. (2013) Inflammation in obesity and diabetes: islet dysfunction and therapeutic opportunity. Cell metabolism, Vol. 17, H. 6. pp. 860-872.

Timper, K. and Hruz, P. and Beglinger, C. and Donath, M. Y.. (2013) Infliximab in the treatment of Crohn disease and type 1 diabetes. Diabetes care, Vol. 36, H. 7 , e90-e91.

Moran, A. and Bundy, B. and Becker, D. J. and DiMeglio, L. A. and Gitelman, S. E. and Goland, R. and Greenbaum, C. J. and Herold, K. C. and Marks, J. B. and Raskin, P. and Sanda, S. and Schatz, D. and Wherrett, D. K. and Wilson, D. M. and Krischer, J. P. and Skyler, J. S. and Pickersgill, L. and de Koning, E. and Ziegler, A. G. and Boehm, B. and Badenhoop, K. and Schloot, N. and Bak, J. F. and Pozzilli, P. and Mauricio, D. and Donath, M. Y. and Castano, L. and Wagner, A. and Lervang, H. H. and Perrild, H. and Mandrup-Poulsen, T. and Aida Study Group, and Pociot, F. and Dinarello, C. A.. (2013) Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials. Lancet, Vol. 381, no. 9881. pp. 1905-1915.

Tang, C. and Naassan, A. E. and Chamson-Reig, A. and Koulajian, K. and Goh, T. T. and Yoon, F. and Oprescu, A. I. and Ghanim, H. and Lewis, G. F. and Dandona, P. and Donath, M. Y. and Ehses, J. A. and Arany, E. and Giacca, A.. (2013) Susceptibility to fatty acid-induced beta-cell dysfunction is enhanced in prediabetic diabetes-prone biobreeding rats: a potential link between beta-cell lipotoxicity and islet inflammation. Endocrinology, Vol. 154, H. 1. pp. 89-101.

Donath, M. Y.. (2013) Targeting inflammation in the treatment of type 2 diabetes. Diabetes, obesity and metabolism, Vol. 15, suppl. 3. pp. 193-196.

Donath, M. Y.. (2013) When metabolism met immunology. Nature immunology, Vol. 14, H. 5. pp. 421-422.

2012

Erener, S. and Mirsaidi, A. and Hesse, M. and Tiaden, A. N. and Ellingsgaard, H. and Kostadinova, R. and Donath, M. Y. and Richards, P. J. and Hottiger, M. O.. (2012) ARTD1 deletion causes increased hepatic lipid accumulation in mice fed a high-fat diet and impairs adipocyte function and differentiation. The FASEB Journal, Vol. 26, H. 6. pp. 2631-2638.

Timper, K. and Donath, M. Y.. (2012) Diabetes mellitus Type 2 - the new face of an old lady. Swiss medical weekly, Vol. 142 , w13635.

Cavelti-Weder, C. and Babians-Brunner, A. and Keller, C. and Stahel, M. A. and Kurz-Levin, M. and Zayed, H. and Solinger, A. M. and Mandrup-Poulsen, T. and Dinarello, C. A. and Donath, M. Y.. (2012) Effects of gevokizumab on glycemia and inflammatory markers in type 2 diabetes. Diabetes care, Vol. 35, H. 8. pp. 1654-1662.

Rutti, S. and Sauter, N. S. and Bouzakri, K. and Prazak, R. and Halban, P. A. and Donath, M. Y.. (2012) In vitro proliferation of adult human beta-cells. PLoS ONE, Vol. 7, H. 4 , e35801.

Cavelti-Weder, C. and Muggli, B. and Keller, C. and Babians-Brunner, A. and Biason-Lauber, A. and Donath, M. Y. and Schmid-Grendelmeier, P.. (2012) Successful use of omalizumab in an inadequately controlled type 2 diabetic patient with severe insulin allergy. Diabetes care, Vol. 35, H. 6 , e41.

2011

Bouzakri, K. and Plomgaard, P. and Berney, T. and Donath, M. Y. and Pedersen, B. K. and Halban, P. A.. (2011) Bimodal effect on pancreatic β-cells of secretory products from normal or insulin-resistant human skeletal muscle. Diabetes, Vol. 60, H. 4. pp. 1111-1121.

Ellingsgaard, H. and Hauselmann, I. and Schuler, B. and Habib, A. M. and Baggio, L. L. and Meier, D. T. and Eppler, E. and Bouzakri, K. and Wueest, S. and Muller, Y. D. and Hansen, A. M. and Reinecke, M. and Konrad, D. and Gassmann, M. and Reimann, F. and Halban, P. A. and Gromada, J. and Drucker, D. J. and Gribble, F. M. and Ehses, J. A. and Donath, M. Y.. (2011) Interleukin-6 enhances insulin secretion by increasing glucagon-like peptide-1 secretion from L cells and α-cells. Nature medicine, Vol. 17, H. 11. pp. 1481-1489.

Donath, M. Y. and Shoelson, S. E.. (2011) Type 2 diabetes as an inflammatory disease. Nature reviews. Immunology, Vol. 11, H. 2. pp. 98-107.

This list was generated on Tue Nov 12 03:26:11 2019 CET.